Myfortic Articles
Access to many more medicines in Australia, as PBS list extended
28 October 2012
Study suggests TDM for at-risk CellCept patients
18 August 2008
FDA reissues warning on mycopheno drugs
26 May 2008
Stock Commentary - Europe - week to April 14, 2008
21 April 2008
FDA starts safety review of Roche's CellCept and Novartis' Myfortic after cases of PML
21 April 2008
Myfortic cuts GI effects in transplant recipients
14 January 2008
Novartis' Myfortic launched in UK
20 September 2004
Stock Commentary - Europe
15 March 2004
Novartis' Myfortic cleared by FDA
8 March 2004
Novartis' Myfortic completes EU's MRP
16 February 2004
New Chemical Entities in 2003
19 January 2004
New data on Novartis transplant drugs
6 May 2002
Novartis files Myfortic in Europe
1 November 2001
Showing 1-17 of 17 articles
- 1
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
